Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Ranbaxy Obtains Approval To Market Ran-Rosuvastatin In Canada - Quick Facts

Ranbaxy Pharmaceuticals Canada Inc. or RPCI, a wholly owned subsidiary of Ranbaxy Laboratories Limited, announced that RPCI has received approval from Health Canada to manufacture and market RAN-Rosuvastatin tablets to the Canadian healthcare system. Rosuvastatin is a HMG-COA Reductase Inhibitor (cholesterol-lowering medication). Brand sales of Crestorin Canada were $742.2 million.

"The finished dosage form was developed, and will be manufactured within RLL's Health Canada approved facilities located in India. We anticipate making Rosuvastatin tablets available to all classes of trade after April 2 when sufficient supplies are available to meet market demand," said Paul Drake, President and General Manager of RPCI.

Click here to receive FREE breaking news email alerts for RANBAXY LABS LTD and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Reserve Bank of India kept its key rates unchanged once again as expected, citing upside risks to medium-term inflation target. The decision announced Tuesday meant that the repo rate was left unchanged at 8.00 percent for the fourth straight policy meeting. The repo rate is the rate at which the central bank lends to commercial banks. The Reserve Bank of India kept its key rates unchanged once again as expected, citing upside risks to medium-term inflation target. The decision announced Tuesday meant that the repo rate was left unchanged at 8.00 percent for the fourth straight policy meeting. The repo rate is the rate at which the central bank lends to commercial banks. U.K. house prices unexpectedly declined in September after rising for sixteen straight months amid signs that demand may be starting to ease, the results of a survey by the Nationwide Building Society showed Tuesday. The house price index dropped 0.2 percent from August, when it climbed 0.8 percent....
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.